Last reviewed · How we verify
22nd Century Group, Inc. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Nicotine gum (C) | Nicotine gum (C) | marketed | Nicotinic acetylcholine receptor agonist | Nicotinic acetylcholine receptors | Addiction Medicine / Smoking Cessation |
Therapeutic area mix
- Addiction Medicine / Smoking Cessation · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Instituto Fernandes Figueira · 1 shared drug class
- Iowa City Veterans Affairs Medical Center · 1 shared drug class
- Johns Hopkins University · 1 shared drug class
- Medical University of Vienna · 1 shared drug class
- Ottawa Hospital Research Institute · 1 shared drug class
- University of Auckland, New Zealand · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for 22nd Century Group, Inc.:
- 22nd Century Group, Inc. pipeline updates — RSS
- 22nd Century Group, Inc. pipeline updates — Atom
- 22nd Century Group, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). 22nd Century Group, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/22nd-century-group-inc. Accessed 2026-05-16.